Dexamethasone for treating SARS-CoV-2 infection
a systematic review and meta-analysis
Keywords:
Dexamethasone, COVID-19, SARS-CoV-2, Meta-analysis [publication type], Pulmonary medicineAbstract
BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO PLATFORM: CRD42021229825.
Downloads
References
Center for Systems Science and Engineering, Johns Hopkins University. COVID-19 dashboard [Internet]. 2021. Available from: Available from: https://coronavirus.jhu.edu/map.html Accessed in 2021 (Jun 23).
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44. PMID: 32123347; https://doi.org/10.1038/s41564-020-0695-z.
Campbell CM, Guha A, Haque T, Neilan TG, Addison D. Repurposing immunomodulatory therapies against coronavirus disease 2019 (Covid-19) in the era of cardiac vigilance: a systematic review. J Clin Med. 2020;9(9):2935. PMID: 32932930; https://doi.org/10.3390/jcm9092935.
WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results [Internet]. Infectious Diseases (except HIV/AIDS); 2020. Available from: Available from: http://medrxiv.org/lookup/doi/10.1101/2020.10.15.20209817 Accessed in 2021 (Jan 6).
Sharun K, Tiwari R, Dhama J, Dhama K. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence. Int J Surg. 2020;82:179-81. PMID: 32896649; https://doi.org/10.1016/j.ijsu.2020.08.038.
Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: Who won and who lost? Clin Mol Allergy [Internet]. 2020;18(1). Available from: Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L632824311&from=export Accessed in 2021 (Feb 14).
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020. Available from: Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L632383122&from=export Accessed in 2021 (Feb 14).
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-16. PMID: 32876695; https://doi.org/10.1001/jama.2020.17021.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. PMID: 22008217; https://doi.org/10.1136/bmj.d5928.
Nordic Cochrane Centre, Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4. 2020.
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019 Mar 14;5(1):1-22. PMID: 30872586; http://doi.org/10.1038/s41572-019-0069-0.
Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Resp Med. 2019; 8(12):1233-44. PMID: 33075298; http://doi.org/10.1016/S2213-2600(20)30404-5.
U. S. National Library of Medicine. Clinical Trials [Internet]. Bethesda: Clinical Trials; 2021 [cited 2021 Jun 22]. Available from: Available from: https://clinicaltrials.gov/ct2/results?term=dexamethasone&cond=Covid19 Accessed in 2021 (Jul 12).
Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 ;8(3):267-76. PMID: 32043986; https://doi.org/10.1016/S2213-2600(19)30417-5.
Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ. 2020;192(27):E756-67. PMID:32409522; https://doi.org/10.1503/cmaj.200645.
The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671-84. PMID: 16625008; https://doi.org/10.1056/NEJMoa051693.
Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med. 2020; 48(2):e98-106. PMID: 31939808; https://doi.org/10.1097/CCM.0000000000004093.
Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med. 2021; 3: 919-923. PMID: 33644693; https://doi.org/10.1007/s42399-021-00824-4.
